NCT01473108 - Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

May 17, 2011

Conditions

Clinical Pharmacology

Interventions

DRUG

Finerenone (BAY 94-8862) PEG solution

2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862

DRUG

Finerenone (BAY 94-8862) immediate release tablet

20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets

DRUG

Eplerenone (Inspra®)

Single oral dose of 50 mg eplerenone

DRUG

Placebo

Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step

Trial Locations (1)

Neuss